Genetraks raises $6m
Wednesday, 18 December, 2002
Genetraks, a start-up biotech developing blood tests for use in pre-race evaluation of animals such as racehorses, has received a $6 million injection of venture capital.
The commercial potential of its technology for assessing the health of racing animals with a view to maximising their performance has helped the company win investment interest in a difficult market.
The Brisbane company, which received earlier support from St George Innovation Fund and a $246,380 Biotechnology Innovation Fund (BIF) grant, is based on bioinformatics techniques. Its technology relates to the diagnostic capacity of gene expression 'signatures' in white blood cells in immune-mediated diseases.
The company is led by two veterinary PhDs, Rosalyn and Richard Brandon, who respectively are its CEO and biotechnology director.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
